← Eichor
Study identifier: NCT05653453 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

Condition: Locally Advanced Pancreatic Cancer  ·  Sponsor: Jiangsu Healthy Life Innovation Medical Technology Co., Ltd

PhasePhase 3
Planned participants512
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Fu  ·  021-52889999  ·  Surgeonfu@163.com

Always discuss trial participation with your own doctor first.

Locations (5)

Harbin Medical University Cancer HospitalHarbin, Heilongjiang, ChinaRecruiting
Cancer Hospital of Shandong First Medical UniversityJinan, Shandong, ChinaRecruiting
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, ChinaRecruiting
Fudan University Affiliated Huashan HospitalShanghai, Shanghai Municipality, ChinaRecruiting
Huashan Hospital Affiliated to Fudan UniversityShanghai, Shanghai Municipality, ChinaNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05653453